Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136077) titled 'A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy' on Aug. 18.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Minimal Residual Disease
Adjuvant Chemotherapy
Colorectal Cancer
Fruquintinib
Tislelizumab
ctDNA
Intervention:
Drug: Tislelizumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 5, 20...